Energía solar térmica de concentración

QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF

Resumen de: US20260109684A1

0000 Quinoline compounds are disclosed that have a formula represented by the following; and wherein Cy, R1, R4a, R4b, and n are as described herein. The compounds may be prepared as compositions, e g., pharmaceutical compositions, or as dosage forms, e.g., pharmaceutical dosage forms, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease, COVID-19 complications, and other diseases related to RAGE activity.

VACCINE ADJUVANTS AND FORMULATIONS THEREOF

Resumen de: WO2026085355A1

The present disclosure pertains to the field of vaccine technologies, with a focus on improved vaccine adjuvants and their formulations for enhancing immune responses. The described approach addresses limitations of traditional adjuvants by introducing novel formulations of the TLR7 agonist 1 V270, either as a standalone agent or in combination with co-adjuvants such as 2G272 and 2E151. These formulations include self-assembling nanoparticles, lipid-incorporated nanoparticles, and aqueous or liposomal combinations, designed to enhance antigen-specific immune responses while maintaining favorable safety and stability profiles. Notable advantages include balanced Thl/Th2 immune responses, dose¬ sparing effects, cross-reactive immunity, and compatibility with modern vaccine platforms such as mRNA vaccines. Applications encompass systemic and mucosal immunization against a wide range of pathogens, including influenza, SARS-CoV-2, and other infectious diseases. The described approach demonstrates enhanced immunogenicity, durability, and efficacy, particularly in aged populations and those requiring heterologous prime-boost regimens.

HLA CLUSTERS, GLOBAL FREQUENCIES, & BINDING ACROSS SARS-CoV-2 VARIATION

Resumen de: US20260112446A1

0000 Techniques are provided for determining pan-HLA binding of viral proteins. A trained classifier model is operable to determine, independently per HLA, at least one of (a) an average binding prediction of overlapping peptides at each position of a viral protein, (b) a maximum value of a binding prediction of overlapping peptides at each position of the viral protein, (c) standard deviation of a binding prediction of overlapping peptides at each position of the viral protein, and (d) a combination of one or more of (a)-(c). A classification engine uses the classifier model to determine average binding predictions of overlapping peptides at each position of the viral protein independently for test HLA-I and HLA-II functional groupings, where a peptide is classified as a binder when an average binding prediction corresponding to the peptide satisfies a binding value threshold.

PEPTIDE WITH NEUTRALIZING ACTIVITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Resumen de: US20260109734A1

0000 The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof, a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.

SARS-COV-2 ANTIBODIES AND METHODS OF USING THE SAME

Resumen de: US20260109754A1

0000 The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2, e.g., an infection in subject.

ANTIBODY MRNA FOR TREATING SARS-CORONAVIRUS-2 DELTA INFECTION AND COMPOSITION INCLUDING SAME

Resumen de: US20260108597A1

0000 The present invention relates to an antibody mRNA for treating SARS-coronavirus-2 delta infection and a composition including same, the composition exhibiting excellent therapeutic efficacy against SARS-coronavirus-2 delta infection.

NOBLE COLD-ADAPTED ATTENUATED MERS-COV

Resumen de: US20260108596A1

The present invention relates to a novel cold-adapted attenuated Middle East respiratory syndrome coronavirus (MERS-CoV) and uses thereof. According to the present invention, the novel attenuated Middle East respiratory syndrome coronavirus (MERS-CoV) capable of effectively preventing infection with MERS-CoV has been developed by cold-adapting the MERS-CoV gradually, and thus can be effectively used as vaccines and therapeutic agents capable of preventing and treating Middle East respiratory syndrome.

SARS-COV-2 MPRO INHIBITORS AND USES THEREOF

Resumen de: US20260109672A1

This application relates to novel compounds and their use as SARS-CoV-2 Main Protease (Mpro) inhibitors. Compounds described herein may be useful in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The application is also directed to pharmaceutical compositions comprising these compounds and the manufacture and use of these compounds and compositions in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2: Mpro. The compounds and compositions may be useful in preventing death or complications arising due to chronic underlying conditions or comorbidities in patients infected with SARS-CoV-2 and related viruses.

VIRUS-LIKE PARTICLES FOR THE TREATMENT OF SARS-COV2

Resumen de: WO2024257026A1

The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).

MODIFIED ACE2 PROTEINS WITH IMPROVED ACTIVITY AGAINST SARS-COV-2

Resumen de: US20260102474A1

The present invention relates to therapeutic proteins and medical uses thereof. The present invention relates to modified ACE2 protein having increased binding affinity for the SARS-COV-2 spike protein compared to wildtype ACE2 protein, wherein said modified ACE2 protein is lacking enzymatic activity and is fused to (i) a modified Fc domain of human immunoglobulin, wherein the Fc domain has either enhanced immunostimulating activity (Fc+) or attenuated immunostimulating activity (Fc−) or (ii) a protein that specifically binds to T cells or further enhances immunostimulating activity. The invention also relates to a polynucleotide encoding the modified ACE2 protein of the present invention, a vector or expression construct comprising the polynucleotide, a host cell comprising the polynucleotide or the vector or expression construct, and a non-human transgenic organism comprising the polynucleotide or the vector or expression construct. Moreover, the present invention relates also to a method for the manufacture of a modified ACE protein according to the present invention and to a medicament comprising the modified ACE2 protein, the polynucleotide or the vector or expression construct of the invention. Furthermore, the invention relates to medical uses of the modified ACE2 protein, the polynucleotide or the vector or expression construct in treating and/or preventing a disease or disorder associated with SARS-COV-2 infection. Finally, the invention provides a kit comprising t

SARS-COV2 ANTIBODIES AND METHODS OF USE THEREOF

Resumen de: US20260103506A1

The present disclosure is directed to antibodies and antigen binding fragments thereof, having improved binding specificity for coronaviruses, such as SARS-CoV-2, including neutralizing antibodies. Other embodiments contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.

CORONAVIRUS SPIKE PROTEIN VARIANTS

Resumen de: AU2024354738A1

Provided are coronavirus spike protein variants for use as antigens for vaccines for coronavirus infections.　The present invention provides coronavirus spike protein variants comprising (a) a receptor binding domain (RBD) formed from the amino acid sequence set forth in SEQ ID NO: 1, (b) an RBD formed from an amino acid sequence in which one to several amino acids have been substituted, deleted, inserted, or added in the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1, or (c) an RBD formed from an amino acid sequence having at least 90% sequence identity with the amino acid sequence set forth in SEQ ID NO: 1, and having neutralizing antibody-inducing activity against SARS-CoV-2 and SARS-CoV-1 equivalent to RBD formed from the amino acid sequence set forth in SEQ ID NO: 1.

Method of Treatment of SARS-CoV2 and Lewy-Body Spectrum Dementia Diseases

Resumen de: US20260102421A1

A method of treatment of Sars-COV-2 viral infections including Covid-19 and long Covid and of virus associated cognitive impairment and Lewy-Body Spectrum Dementia disorders in a six-agent treatment regimen of hydroxychloroquine, azithromycin, zinc, quercetin, vitamin C, and vitamin D3. The six-agent treatment is administered to the subject orally for, preferably, 5 days at which time the subject is cured of Covid-19. In an alternant embodiment, the method comprises administering to a subject an eight-agent treatment regimen of hydroxychloroquine, azithromycin, zinc, quercetin, vitamin C, vitamin D3, pregnenolone, and niacinamide. The addition of pregnenolone, and niacinamide to the six-agent treatment enhances the improvement of cognitive performance.

CYSTEAMINE FOR THE TREATMENT, MITIGATION AND PREVENTION OF CORONAVIRAL, E.G., SARS-CoV-2, INFECTIONS

Resumen de: US20260097007A1

0000 Provided herein are methods for the treatment, mitigation, and prevention of viral infections (e.g., coronavirus infections (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etc.), etc.) and diseases (e.g., Coronavirus disease 2019 (COVID-19)) associated therewith by the administration of cysteamine or derivatives thereof to a subject.

CANNABICHROMENE AS A THERAPEUTIC MODALITY FOR COVID-19

Resumen de: US20260097051A1

Compositions and methods for treating or reducing symptoms of acute respiratory distress syndrome (ARDS) generally and COVID-19 infection, in particular, are provided. An exemplary method includes administering to the subject an effective amount of cannabichromene to reduce acute respiratory distress caused by ARDS generally and COVID-19 infection, in particular.

BIOMARKERS IN LONG-COVID-19

Resumen de: US20260098868A1

A method of diagnosing long-COVID-19 in a patient, the method comprising: (a) obtaining a test sample from the patient, (b) performing one or more assays configured to detect a level of one or more biomarkers in the test sample, (c) comparing the level of the one or more proteins in the test sample with a healthy control reference value of said one or more proteins, wherein a change in the level of the one or more biomarkers in the test sample relative to the healthy control reference value of said one or more proteins is indicative of long-COVID-19 diagnosis, wherein the one or more proteins are selected from Table 3.

ENGINEERED PHAGE AND KIT FOR CAPTURING SARS-COV-2 AND METHOD FOR DETECTING SARS-COV-2 VIRUS BY MEANS OF SAID PHAGE OR KIT

Resumen de: US20260098861A1

A phage for the specific capture of the SARS-CoV-2 virus, said phage being an M13 phage engineered to display on the P8 protein of its coat either FHKGGYEKTWKLGD sequence peptides or EFTSKAR sequence peptides, said peptides having specific affinity for the Spike S1 protein of the SARS-CoV-2 virus.

IMMUNOGENIC COMPOSITIONS AND USE THEREOF

Resumen de: US20260097115A1

0000 Immunogenic compositions comprising one or more peptides, wherein the one or more peptides: are capable of binding to Major Histocompatibility Complex (MHC) class II, and are derived from one or more translation products of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.

Methods for the Rapid Manufacture of Conjugate Vaccines that Elicit Robust Immune Responses

Resumen de: US20260097114A1

The disclosures of the invention are directed to the manufacture of effective, affordable vaccines that are globally accessible. Using a platform conjugation technology, highly immunogenic conjugate vaccines were produced that elicit broad cross-neutralization to variants of concern (VOC), manufactured cheaply compared to mRNA vaccines. Protein-protein conjugates and Toll-Like Receptor (TLR) agonist adjuvants were shown to enhance immunogenicity and induce broad cross-protection against VOC, a characteristic lacking in early mRNA COVID-19 vaccines. Murine nAb titers from Beta-only conjugates were equivalent between Beta, Delta, Omicron BA.1, BA.2, and BA.4/BA.5, which were circulating up to three years after the antigenic strain. Additionally, Beta-Delta bivalent conjugate vaccines readily prevented disease in hamster challenge, which demonstrates a vaccine with remarkably broad cross-protection and potential to protect for extended periods despite mutations, without requiring expensive boosters or antigen adaption. This vaccine can be produced in our highly automated, large-scale manufacturing facility enabling economical production of inexpensive, effective vaccines for high-need areas.

CORONAVIRUS VACCINE COMPOSITION, METHOD THEREFOR AND USE THEREOF

Resumen de: EP4722230A1

0001 The present invention relates to an immunogenic composition comprising a recombinant peptide and protein, wherein the recombinant peptide and protein comprise a coronavirus antigen and immunogen, for example, a chimeric antigen and immunogen of an S protein peptide or a fragment, variant or mutant sequence thereof of SARS-CoV-2 Hu-1, SARS-CoV-2 Omicron (BA.5 and/or XBB.1.5) variant, and/or other variants. The immunogenic composition comprises a secreted fusion protein, which comprises a soluble coronavirus antigen, wherein the soluble coronavirus antigen protein is linked, by means of in-frame fusion, to a C-terminal moiety of a collagen capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. The immunogenic composition can be used for generating an immune response, and can be used in a vaccine composition. Further provided are methods for producing a recombinant peptide and protein, methods for prevention, treatment and/or diagnosis, and a related kit.

BIOSYNTHESIS METHOD FOR BROAD-SPECTRUM ANTIVIRAL POLYPEPTIDE

Resumen de: EP4722231A1

A biosynthesis method for a broad-spectrum antiviral polypeptide. The present invention specifically relates to a biosynthesis method for a polypeptide HCoV-EK1 capable of inhibiting human coronavirus infections in a broad-spectrum manner. The specific process comprises: construction of an Escherichia coli genetically engineered bacterium, fermentation culture of the Escherichia coli genetically engineered bacterium, and purification of recombinant polypeptide HCoV-EK1.

METHOD FOR POLARIZATION-PHASE INTERFEROMETRY OF THE OPTICALLY ANISOTROPIC ARCHITECTONICS OF FIBRILLAR AND PARENCHYMAL TISSUE SPECIMENS FROM DECEASED INDIVIDUALS WHO SUFFERED FROM COVID-19

Resumen de: UA162619U

Method for polarization-phase interferometry of the optically anisotropic architectonics of fibrillar and parenchymal tissue specimens from deceased individuals who suffered from COVID-19, by means of polarization mapping of laser microscopic images of native histological sections of biological tissues with algorithmic reconstruction of integrated average phase maps of the polycrystalline architectonics of biological layers through the measurement of coordinate distributions of partial elements of the polarization matrix. To evaluate changes in the layer-by-layer phase maps of the optically anisotropic architectonics of fibrillar (myocardium) and parenchymal (kidney) tissue specimens from the deceased, native histological section samples of deceased individuals who suffered from COVID-19 are placed in the optical beam path of a Mach-Zehnder polarization interferometer. A series of plane-polarized (with polarization azimuths of 0°, 90°, 45°, 135°) and circularly left-hand 5 and right-hand polarized irradiating and reference laser beams are formed; for each polarization state, the irradiating beam is directed by means of a rotating mirror onto the native histological section sample of the deceased who suffered from COVID-19, the laser image of which is projected by a polarization micro-objective into the plane of photosensitive pixels of a digital camera, while a series of reference beams with polarization states of 0°, 90°, 45°, 135°, a, , are sequentially directed by

INHIBITING 20S PROTEASOME SUBUNITS β2 AND β6 AND β-TRANSDUCIN REPEAT-CONTAINING PROTEIN AS ANTIVIRAL THERAPIES

Resumen de: WO2026072651A1

A method of treating a viral disease associated with targeting of PDZ domain proteins by a viral disease-inducing virus, in a subject in need of such therapy, comprising administering to the subject an inhibitor of at least one of 20s proteasome subunit β6 (Prosβ6), 20s proteasome subunit β2 (Prosβ2), and β-Transducin repeat-containing protein (βTrCP), thereby causing the death of cells that have been infected by the viral disease-inducing virus. The viral disease-inducing virus may be, for example, HPV, Adenovirus, Influenza A, HTLV-1, HIV, West Nile, Dengue, or SARS-CoV. Hie HPV may be a high-risk HPV strain such as HPV strain 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, or 68. The viral disease may be an HPV-induced cancer.

SARS-COV-2 RECEPTOR BINDING DOMAIN NANOPARTICLES AND METHODS OF USE THEREOF

Resumen de: WO2026073202A1

Disclosed herein are receptor binding domain (RBD) SARS-CoV-2 immunogens, engineered nanoparticle vaccines comprising receptor binding domain (RBD) SARS-CoV-2 immunogens and methods of use thereof for SARS- CoV-2 vaccines.

METHOD FOR PREVENTING INFECTION OF A HEALTHY PERSON OR A HEALTHY ANIMAL WITH A VIRUS THAT USES ACE2 AS A RECEPTOR, BINDING INHIBITOR AND MEDICAL DEVICE

Resumen de: US20260091066A1

A composition containing a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells, umbilical cord-derived stem cells or immortalized stem cells thereof in which the composition contains angiotensin-converting enzyme 2 (ACE2) and is used for administration to a healthy person or a healthy animal for preventing infection of the healthy person or the healthy animal with a virus that uses ACE2 as a receptor can be used as a medicine for preventing infection with a virus that uses ACE2 as a receptor, such as COVID-19, or the like when administered to a healthy person or a healthy animal.

CORONAVIRUS VACCINE

Resumen de: US20260091107A1

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus Infection, preferably a Coronavirus infection.

N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO

Resumen de: UA130623C2

This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.

Use of nucleoside compound in treatment of coronavirus infectious diseases

Resumen de: NZ791549A

Use of a compound represented by formula (I) or pharmaceutically acceptable salts thereof in the preparation of drugs for preventing or treating coronavirus infectious diseases. The compound represented by formula (I) is used for treating patients with novel coronavirus pneumonia, and shows obvious advantages in negative conversion ratio of viral nucleic acid test, negative conversion course, and cure and hospital discharge time.

LAMP ASSAY SYSTEM FOR DETECTION OF RESPIRATORY VIRUS

Resumen de: US20260085367A1

A LAMP assay system for detection of a respiratory virus is disclosed. The LAMP system includes a LAMP reaction mixture having a primer kit, a strand-displacing polymerase and deoxyribonucleoside triphosphates for amplifying a target sequence. The primer kit includes at least one of a first primer set specific to SARS-CoV-2, a second primer set specific to Influenza A, and a third primer set specific to Influenza B. The first primer set includes primers having nucleotide sequences of SEQ ID NOs: 1 to 6 and SEQ ID NOs: 13 to 18. The second primer set includes primers having nucleotide sequences of SEQ ID NOs: 25 to 30. The third primer set includes primers having nucleotide sequences of SEQ ID NOs: 44 to 49.

BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF

Resumen de: US20260085063A1

The present disclosure relates, in part, to SARS-CoV-2 papain-like protease (PLpro) inhibitor compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same for promoting an antiviral effect in a subject and/or treating, preventing, and/or ameliorating a viral infection in a subject:

MEASUREMENT OF LUNG FUNCTIONS BY PULMONARY GAS EXCHANGE

Resumen de: US20260083351A1

Provided are methods and systems for measuring lung function, such as shunt and deadspace, using pulmonary gas exchange in management and treatment of pulmonary diseases including COVID-19.

CHEMICAL COMPOUND COMPRISING A TRIAZINE GROUP AND METHOD FOR PRODUCING SAME

Resumen de: US20260085087A1

A chemical compound having a triazine group and a method for production thereof are related to novel compounds and methods for production thereof in nucleotide chemistry. In particular, the present invention relates to nucleotides and oligonucleotides comprising a modified phosphate group, and to the method for production thereof. The present invention may be used in cytological studies, in DNA- or RNA-containing pathogen diagnostics, in gene therapy as well as in treating various bacterial and viral diseases, including COVID-19. The objective of the present invention is to provide compounds having a therapeutic potential as well as to develop the available method for production thereof.

SYSTEMS AND METHODS FOR TREATING BLOOD CLOTS WITH NERVE STIMULATION

Resumen de: US20260088185A1

Systems and methods are provided for treating blood clots associated with a replicating pathogen, such as a virus in the coronaviridae family. The systems and methods include applying an electrical impulse transcutaneously through the outer skin surface of the patient to a cervical branch of the vagus nerve of the patient. The electrical impulse is sufficient to reduce a number of antibodies associated with blood clotting to reduce a level of blood clotting in the patient. The systems and methods are particularly useful for treating post-COVID conditions or post-acute sequelae of COVID-19 that develop in “long-haul” or COVID patients.

SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION

Resumen de: US20260083762A1

The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).

MODULAR BACTERIOPHAGE T4 NANOPARTICLE PLATFORM ENABLES RAPID DESIGN OF DUAL COVID-19-FLU MUCOSAL VACCINES

Resumen de: US20260083835A1

A non-infections bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.

PANCORONAVIRUS BIOMARKER PANEL

Resumen de: WO2026064358A1

The present disclosure provides pancoronavirus biomarker panels that can be used to detect a wide variety of characterized coronavirus strains and, in some embodiments, emerging or novel coronavirus strains. In certain embodiments, this detection can be carried out in a single, highly multiplexed nucleic acid amplification assay.

METHODS OF TREATING RESPIRATORY DISEASE WITH DEUPIRFENIDONE

Resumen de: EP4714943A2

Disclosed herein is a method of treating a viral, e.g., SARS-CoV-2, respiratory disease or infection, such as COVID-19 related pneumonia, that includes administering deuterium-enriched pirfenidone, e.g., daily for 3 months or more, such that the viral respiratory disease or infection is treated. The treating is effective in preventing the development of, halting the progression of, or slowing the progression of one or more of pulmonary fibrosis, respiratory complications of the viral respiratory disease or infection, respiratory symptoms of the viral respiratory disease or infection or pulmonary dysfunction.

METHODS FOR TREATING SARS COV-2 INFECTIONS

Resumen de: EP4714452A1

Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I:wherein the l' position of the nucleoside sugar is substituted.

S-RBD Electrochemical Detection of S-RBD Protein for Point-of-Care SARS-CoV-2 Monitoring Using Platinum-Black-Based Sensor Array and Manufacturing Method Thereof

Resumen de: KR20260039239A

본 발명은 코로나 바이러스 진단을 위한 전기화학적 S-RBD 단백질 검출 센서 및 그 제조 방법에 관한 것으로, 본 발명에 따른 전기화학적 S-RBD 단백질 검출 센서는 유리 기판 상에 형성된 골드 마이크로디스크(microdisk) 전극 어레이(array); 및 상기 금 마이크로디스크 전극 어레이 상에 증착된 Pt-black(플래티넘 블랙) 층을 포함하고, 상기 Pt-black 층은 SAM(self-assembled monolayer) 층으로 개질(modification) 된다.

PROTAC DEGRADERS OF SARS-COV-2 MAIN PROTEASE

Resumen de: US20260077050A1

The present disclosure relates to certain molecules, pharmaceutical compositions containing them, and methods of using them to treat viral infections.

METHOD AND REAGENTS FOR ULTRASENSITIVE IMMUNOASSAY

Resumen de: US20260079158A1

Disclosed are assays, reagents, and methods for ultrasensitive detection of target molecules. The assay comprises fusion proteins including binding moieties, such as antibodies, nanobodies (VHH/VNAR), or aptamers, linked to nonfunctional fragments of a protein. In the presence of a target molecule, the binding moieties recognize distinct target regions and bring the protein fragments into close proximity, reconstituting a functional protein that generates a detectable signal. Linkers connecting the fusion components may be flexible peptides or polypeptides that spontaneously form dimers, trimers, or tetramers, thereby providing multivalent fusion proteins with enhanced sensitivity. The reconstituted protein may produce luminescent, fluorescent, colorimetric, or spectroscopic signals detectable by microplate readers, handheld luminometers, or lateral flow devices. The invention encompasses solid-phase, homogeneous, and lateral flow assay formats for detecting viruses, bacteria, proteins, peptides, or small molecules, including GLRaV-3, SARS-CoV-2, PSA, and E. coli. The disclosed assays exhibit improved specificity, reduced background, and enhanced signal-to-noise ratios.

Pan-Neutralizing SARS-CoV-2 mAb Composition and Methods of Treatment Thereof

Resumen de: US20260078170A1

Among the various aspects of the present disclosure is the provision of compositions and methods of use of mAb that prevent, inhibit, or reduce the transmissivity of SARS-CoV-2 infections.

COMPOSITION FOR THE TREATMENT OF COVID-19

Resumen de: US20260076980A1

A composition and method for treating COVID-19 includes a first component including approximately 10 mg of dexamethasone and a second component including approximately 48 mg to 80 mg of triamcinolone acetonide in combination with sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80. When combined, the formulation provides dual-steroid therapy that reduces the need for tapering associated with high-dose dexamethasone, thereby minimizing adverse effects such as immunosuppression and secondary pneumonia. The composition is administered via injection and is effective for alleviating symptoms in patients with mild, moderate, or severe COVID-19 infections.

PREPARATION METHOD AND APPLICATION OF RECOMBINANT PROTEIN OF NOVEL CORONAVIRUS OR RECOMBINANT PROTEIN OF HUMAN ANGIOTENSIN CONVERTING ENZYME-2

Resumen de: NL2038573B1

The present invention relates to the technical field of genetic engineering of molecular biology and medical science, and specifically discloses a preparation method and application of recombinant protein of novel coronavirus or recombinant protein of human angiotensin converting enzyme—2. According to the present invention, the two recombinant proteins are prepared in Escherichia coli of a prokaryotic system by using genetic engineering technology, which can be successfully and efficiently expressed, have good antigenicity, and can be well configured to detect a neutralizing antibody of the novel coronavirus. Compared with other traditional methods, the present invention is safer and more efficient, and has positive significance for basic research and clinical detection in the novel coronavirus.

TOUCHLESS COMPUTER INTERFACES

Resumen de: US20260080738A1

This application is directed to touchless interfaces. Some embodiments disclosed are directed to plug and play replacements for casino gaming machine touch-based interfaces on, e.g., slot machines. Existing slot machine interfaces can be replaced with touchless interfaces of the inventive subject matter to enable touchless interaction with gaming machines. This allows people in casinos to minimize contact with gaming machines to stymy the spread of diseases like COVID-19.

IMMUNIZATION METHOD AGAINST INFECTION BY SARS-CoV-2

Resumen de: US20260077035A1

A pDNA-based vaccine against SARS-CoV-2 and methods for preventing or treating COVID-19 using it.

TRACHEAL INTRODUCER SHEATH AND SIMPLIFIED TRACHEAL INTRODUCER SHEATH

Resumen de: US20260077146A1

According to the CDC, the same month (March, 2020) they declared COVD-19 a pandemic, nearly 25% of confirmed COVID-19 hospitalized patients required intubation, or ventilator use. More recently, in the US, during the summer of 2021, child intubations more than quadrupled, when the Delta variant predominated.As Omicron and additional COVID-19 variants continue to arise globally, there will be an increasing number of sudden spikes in critical illness and respiratory failure. Preparedness with efficacious airway tools that optimize success rate of intubations is critical.Without the proper tools, intubation procedures take excessive time, and can fail entirely, causing diminished central nervous system oxygenation and potentially permanent neurologic sequelae. Airway adjuncts such as the Tracheal Introducer Sheath (TIS) and Simplified Tracheal Introducer Sheath (STIS) hold immense potential to improve chances of successful intubations.The TIS is a STIS with an added articulating mechanism, but otherwise is a similar device. For the purposes of further explanation, the TIS refers to both TIS and STIS unless otherwise specified.TIS is an adjunct medical device for control and guidance of any form of tracheal introducer device through the glottic opening of a patient's airway. This facilitates endotracheal intubation by passage of the endotracheal tube.An airway introducer is placed within and controlled by the TIS, a mechanically specialized sheath, open at both ends, and covering

SARS-COV2 ANTIBODIES AND USES THEREOF

Resumen de: US20260078171A1

The present disclosure is directed to antibodies and antigen binding fragments thereof, or combinations of antibodies and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. The disclosure contemplates conjugates of anti-CoV-S antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.

Compounds and methods for treating diseases caused by SARS-CoV-2 and other coronaviruses

Resumen de: US20260076973A1

Provided are compounds and methods of treating diseases caused by a Coronaviridae virus such as SARS-CoV-2, SARS-CoV, and MERS-CoV coronaviruses by administering nitrogen-containing heterocyclic compounds. SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), and, particularly, COVID-19 are highly contagious diseases with high mortality rate responsible for tens of millions of infections and almost two million deaths around the globe.

Methods For Reducing Or Preventing SARS-COV-2 Infection And Transmission

Resumen de: US20260077052A1

The application provides a method to prevent or reduce the transmission of a coronavirus, such as a SARS-COV-2 variant, or a paramyxovirus from an infected subject to other uninfected subjects, comprising administrating an anti-viral peptide conjugate to the infected subject, the uninfected subject, or both.

A RECOMBINANT SARS-COV-2 S GLYCOPROTEIN TRIMER, PROTEOLIPOSOMES COMPRISING SUCH A TRIMER AND THEIR USE AS A VACCINE

Resumen de: EP4710948A1

The present invention concerns a recombinant SARS-CoV-2 S glycoprotein trimer stabilized in a conformation that is anterior to the post-fusion conformation, as well as a proteoliposome comprising such a recombinant trimer and a vaccine based on such a proteoliposome. The invention also relates to a method of treating or preventing a SARS-CoV-2 infection in a subject using such a vaccine.

SELF-REPLICATING RNA AND USES THEREOF

Resumen de: EP4711458A2

The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof.

IMMUNOGENIC COMPOSITIONS AND VACCINES IN THE TREATMENT AND PREVENTION OF INFECTIONS

Resumen de: AU2026201333A1

The invention is directed to portions of proteins of gram-positive bacteria, gram-negative, acid-fast bacteria (Mycobacteria, Staphylococcus) and/or virus (SARS-COV-2, Influenza), and antibodies reactive against these portions that can be formulated as immunogenic compositions and vaccines for the treatment and prevention of a microbial and/or viral infections. Preferably, compositions of the invention contain one or more portions of selected microbial and/or viral proteins that, upon administration to a subject, generate an effective cellular and/or humoral immune response, modulate immunity and a cytokine response. Effective responses involve an increased generation of antibodies that enhance immunity against an infection and promote an enhanced a phagocytic response. Monoclonal antibodies produced against these peptides enhance phagocytosis and killing of bacteria, viruses, and other microbes by phagocytic cells, and enhance clearance from the blood. and enhance clearance from the blood. eb e b a n d e n h a n c e c l e a r a n c e f r o m t h e b l o o d

COMPUTERIZED DECISION TOOL FOR SARS-COV-2 VARIANTS PREDICTION

Resumen de: US20260074014A1

Technology is disclosed for a method for screening genetic mutations that can be used to predict vaccine composition, the method may include selecting a plurality of genome samples, partitioning the plurality of genome samples into N groups, where N is an integer larger than 1, identifying genomic isolates with phenotypic statuses from each of the N groups of genome samples by training at least one linear support vector machine with the genome samples, the identification of the isolates between each of the N groups of the genomic isolates performed in parallel, and assessing the identified genomic isolates using a performance metric.

HIGH-AFFINITY PROTEIN BINDERS AND USES THEREOF

Resumen de: WO2026055147A1

Provided herein are proteins that include a Vascular Endothelial Growth Factor A (VEGF-A) protein binding domain; proteins that include an Epstein-Barr Virus BCL-2 homolog (BHRF1) protein binding domain; proteins that include a Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) RBD protein binding domain; proteins that include an Interleukin-7 receptor subunit alpha (IL7R-α) protein binding domain; proteins that include a Programmed death-ligand 1 (PD-L1) protein binding domain; proteins that include a Tropomyosin-receptor kinase A (Trk-A) protein binding domain; and proteins that include an Interleukin-17 (IL-17A) protein binding domain.

Use of N-Chlorotaurine for Treatment and Prevention of Viral Infections

Resumen de: US20260069556A1

Methods for treatment and prevention of a viral infection in an animal, including a respiratory infection, like a coronavirus such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Influenza A such as H1N1, H3N2, H5N1, or respiratory syncytial virus. The compositions and methods include a therapeutically effective amount of about a 1% solution of N-chlorotaurine in water. The methods include administering N-chlorotaurine by eye drop to the eyes, nasal spray to the nostrils, by oral spray to the throat, by nebulizer to the lungs, and by cannula to the mammary glands.

MITOCHONDRIA-FACILITATED DELIVERY OF MRNA

Resumen de: WO2026055709A1

Among the various aspects of the present disclosure is the provision of compositions and methods of a gene delivery system. The compositions include at least one therapeutic molecule and an isolated mitochondria, and optionally further complexed to a lipid nanoparticle. Methods of molecule delivery include the use of isolated mitochondria as a vector for the delivery of the therapeutic molecule. A method of treating a patient in need of a gene vaccine is also described, in which the mRNA of the administered composition encodes a vaccine antigen, including but not limited to at least a portion of a SARS-CoV-2 spike protein.

SARS CORONAVIRUS 2 RECOMBINANT VECTORS EXPRESSING REPORTER GENES, DERIVED FROM GH CLADE SARS CORONAVIRUS 2 OF KOREAN ISOLATE, AND THE PRODUCTION METHOD THEREFOR

Resumen de: US20260071190A1

There are SARS coronavirus 2 recombinant vectors derived from a GH clade SARS coronavirus 2 Korean isolate, which express distinct reporter genes, and the production method thereof. A full-length clone of a SARS coronavirus 2 Korean isolate or a derivative thereof, according to one embodiment, can be used as a standard material for evaluating the efficacy of therapeutic agents and vaccines in cell lines and animal models while maintaining infectivity and replication capacity when restored to viruses, can be used to develop a large-scale testing method for therapeutic agent development, and can be used to develop attenuated vaccine strains. In addition, a SARS coronavirus 2 recombinant vector derived from a Korean isolate or a derivative thereof, expressing a reporter gene, can be used for high-capacity, rapid drug screening in the development of antibody therapeutic agents and antiviral agents.

NUCLEIC ACID VACCINES ENCAPSULATED WITH NANOALUMINOSILICATE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV)

Resumen de: US20260069675A1

A MERS-CoV vaccine with nucleic acid sequences having at least 90% identity to the spike gene of a MERS-CoV strain as a preventive measure against MERS-CoV infections is described. The nucleic acid sequences may include plasmid DNA (pDNA) or messenger RNA (mRNA) that are encapsulated by aluminosilicates. The aluminosilicates may be functionalized with aminopropyltrimethoxysilanes.

METHODS FOR EXPANDING SARS-COV2-ANTIGEN-SPECIFIC T CELLS, COMPOSITIONS AND USES RELATED THERETO

Resumen de: US20260071235A1

Provided herein are methods for preparing and characterizing SARS-cov2 antigen specific immune cell cultures and preparations and methods of using the same in adoptive immunotherapy for cancer, infections, and immune disorders. Also provided are compositions and methods for generating immune calls expressing synthetic antigen binding receptors targeting SARS-cov2 and methods of use of these cells for the treatment and prevention of COVID-19. Also provided are compositions and methods for determining immune response to SARS-cov2 in a subject, detecting SARS-cov2, measuring cytotoxicity induced by SARS-cov2, and detecting the expression and cytotoxicity of synthetic antigen binding receptors targeting SARS-cov2.

ANTI-SARS-COV-2-SPIKE GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS

Resumen de: US20260069689A1

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUND AS PHARMACEUTICAL FOR TREATMENT OR PREVENTION OF COVID-19

Resumen de: EP4707279A1

The present invention provides a compound useful for the treatment or prevention of SARS-CoV-2 novel coronavirus infection.The present invention relates to a compound represented by formula (I), its enantiomer, or a pharmaceutically acceptable salt thereof:whereinring A, R1 and R7, R2 and R4, X and Y, as well as Z are according to the definitions as described in the specification;use thereof for the treatment or prevention of SARS-CoV-2 novel coronavirus infection; and pharmaceutical compositions comprising the same.

SARS-COV-2 VACCINE COMPOSITIONS

Resumen de: AU2024263334A1

Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Immuno-therapeutic chemical compositions and uses thereof

Resumen de: US12569492B1

Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as coronavirus colds and as a therapy against COVID-19. ImmunoFolate has been shown to reduce the incidents of colds and flus. In one embodiment is a method of treating cancer comprising administration of ImmunoFolate. In another embodiment is a method of treatment inflammatory-based disease and disorders comprising administration of ImmunoFolate.

SARS-COV-2 IMMUNOGENIC COMPOSITIONS

Resumen de: WO2026047603A1

Disclosed herein are compositions comprising protein antigens and RNA encoding the same (eg., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can be used to address and/or overcome immune imprinting in SARS-CoV-2.

SARS-COV-2 VACCINES AND THERAPEUTICS

Resumen de: WO2026047716A1

The present disclosure relates generally to receptor binding domain of SARS-CoV- 2 and nucleic acids encoding the receptor binding domain, wherein the receptor binding domain comprises one or more mutations at amino acid positions selected from the group comprising R28T, K38V or T, K126T, F138L, A157V, V165del, E166A or K or P, Q175E, S176P, A202G, or a combination thereof compared to SEQ ID NO: 1. Such a receptor binding domain can be included as one of the components or constituents of polypeptide or multisubunit peptide disclosed herein, including the nucleic acids encoding them.

Combination Vaccine For Prevention Of Influenza And Coronavirus Infections

Resumen de: US20260061046A1

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

SARS-COV-2 RNA VACCINES AND USES THEREOF

Resumen de: MX2025015826A

The present disclosure relates to SARS-CoV-2 RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of a SARS-CoV-2 infection or COVID-19.

KIT Y METODO PARA LA DETECCION Y MEDICION DE ADN, CADN Y ARN DEL SARS-COV-2 Y SUS VARIANTES MEDIANTE SPECTROSCOPY RAMAN MEJORADA POR EFECTOS DE SUPERFICIE (SERS).

Resumen de: MX2024010087A

The invention relates to a biosensor for detecting and quantifying the concentration of up to three genes of interest, for example, the N, E and RdRP genes present in the DNA, cDNA or RNA of the SARS-CoV-2 or any of the variants thereof, by identifying and evaluating the Raman signal emitted by a reporter molecule. The two-component kit: 1) A colloidal solution of nanorollers (NPs) composed of a colloidal solution of gold nanoparticles (NAu) functionalized with a reporter molecule (MR) and conjugated to an oligonucleotide (01) that selectively hybridizes with one of the genes of interest. 2) a capture substrate (SC) having a matrix of up to 3x8 independent thin gold films with a thickness between 40 and 60 nm and diameter between 3 and 5 mm. This substrate is conjugated to another oligonucleotide (02) that selectively hybridizes to another segment of the gene of interest in which the NAu presence is adsorbed to the SC. Two oligonucleotides (01 and 02), a reporter molecule (MR) and a gold film (5) are needed for each gene to be detected. The detection limit of the biosensor is 1 fg/¿L of the gene of interest.

ANTIVIRAL PHARMACEUTICAL FORMULATION BASED ON BIOSYNTHESIZED GOLD NANOHYBRIDS WITH PLANT EXTRACT AND PORPHYRINS

Nº publicación: MX2025014509A 02/03/2026

Solicitante:

UNIV POLITECNICA DE PACHUCA [MX]